Study of Magnetic Fields to Treat Alzheimer's Disease

Inclusion Criteria:

To be considered eligible for participation in this clinical study, a subject must satisfy each of the following "Inclusive Conditions" criteria.

• Current diagnosis of Alzheimer's Disease appropriately documented by the patients physician and/or neurologist
• Documentation verifying that other generally recognized causes of dementia have been ruled out by prior physician evaluations
• Mild to Moderate Dementia, as evidenced by a score of not less than 12 nor greater than 26 on the Mini Mental Status Exam (MMSE).
• Subject is ambulatory
• A Study Partner who can attend all study visits with the subject. Study Partner being defined as an adult who has at least 10 hours/week of contact with the subject, and can accompany the subject to all testing and treatment study visits.
• Stable "anti-dementia" medication regimen without significant side effects for at least 3 months, and on stable medication (unrelated to anti-dementia) without significant side effects for at least 1 month; willingness and ability to maintain the stable medication regimen throughout the course of the study.
• Willingness and ability to present to the testing center for all study evaluations
• Willingness and ability to present to the treatment center for all study treatments (exposure to the Resonator™)
• Willingness to maintain stable diet and activity regimen for the duration of the study.
• Willing and able to abstain from partaking in any non-essential (not physician ordered) existing or new treatments to improve cognition and mental functioning
• Willing and able to abstain from any medications that could affect cognition and mental functioning during the course of the study
• Male or female.
• Any ethnic background.
• Age 55 and older.

Exclusion Criteria A subject will be considered ineligible for participation in this clinical study if he or she satisfies any one or more of the following exclusive conditions criteria.

• Change in anti-dementia medical regimen within 3 months prior to initiation of study.
• Confirmed diagnosis other non-Alzheimer's type of dementia
• Significant neurologic or psychiatric illness other than Alzheimer's disease
• Unstable cardiac disease, such as any history of cardiac arrhythmias (including atrial fibrillation, ventricular fibrillation, or irregular atrial-ventricular conduction time), or any incidences of congestive heart failure, or myocardial infarction, within the last six months.
• Previous surgical interventions involving prosthetics or implants comprised of ferrous metals, or pacemakers, vagus nerve stimulators, or other functional electrical stimulators such as those commonly used for pain.
• Reported consumption of more than 14 alcoholic drinks per week.
• Uncontrolled hypertension.
• Uncontrolled atrial fibrillation or other uncontrolled arrhythmias, e.g. tachycardia, bradycardia.
• Uncontrolled seizure disorder.
• History of seizures or usage of anti-seizure medications that, in the opinion of the investigator, participation in this trial would represent a risk to the subject.
• Uncontrolled, unstable, or untreated medical conditions which may significantly impact the subject's health or ability to complete the entire study, in the opinion of the investigator.